Literature DB >> 28549876

Prediction and analysis of promiscuous T cell-epitopes derived from the vaccine candidate antigens of Leishmania donovani binding to MHC class-II alleles using in silico approach.

Manju Kashyap1, Varun Jaiswal2, Umar Farooq3.   

Abstract

Visceral leishmaniasis is a dreadful infectious disease and caused by the intracellular protozoan parasites, Leishmania donovani and Leishmania infantum. Despite extensive efforts for developing effective prophylactic vaccine, still no vaccine is available against leishmaniasis. However, advancement in immunoinformatics methods generated new dimension in peptide based vaccine development. The present study was aimed to identify T-cell epitopes from the vaccine candidate antigens like Lipophosphogylcan-3(LPG-3) and Nucleoside hydrolase (NH) from the L. donovani using in silico methods. Available best tools were used for the identification of promiscuous peptides for MHC class-II alleles. A total of 34 promiscuous peptides from LPG-3, 3 from NH were identified on the basis of their 100% binding affinity towards all six HLA alleles, taken in this study. These peptides were further checked computationally to know their IFN-γ and IL4 inducing potential and nine peptides were identified. Peptide binding interactions with predominant HLA alleles were done by docking. Out of nine docked promiscuous peptides, only two peptides (QESRILRVIKKKLVR, RILRVIKKKLVRKTL), from LPG-3 and one peptide (FDKFWCLVIDALKRI) from NH showed lowest binding energy with all six alleles. These promiscuous T-cell epitopes were predicted on the basis of their antigenicity, hydrophobicity, potential immune response and docking scores. The immunogenicity of predicted promiscuous peptides might be used for subunit vaccine development with immune-modulating adjuvants.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HLA; Promiscuous peptide; Vaccine candidate antigens; Visceral leishmaniasis

Mesh:

Substances:

Year:  2017        PMID: 28549876     DOI: 10.1016/j.meegid.2017.05.022

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  9 in total

1.  Evaluating complete surface-associated and secretory proteome of Leishmania donovani for discovering novel vaccines and diagnostic targets.

Authors:  Munawwar Karim; Garima Singh; Shweta Thakur; Aarti Rana; Abdur Rub; Yusuf Akhter
Journal:  Arch Microbiol       Date:  2022-09-07       Impact factor: 2.667

2.  Revisiting the Principles of Designing a Vaccine.

Authors:  Shubhranshu Zutshi; Sunil Kumar; Prashant Chauhan; Bhaskar Saha
Journal:  Methods Mol Biol       Date:  2022

3.  Identification of Potential MHC Class-II-Restricted Epitopes Derived from Leishmania donovani Antigens by Reverse Vaccinology and Evaluation of Their CD4+ T-Cell Responsiveness against Visceral Leishmaniasis.

Authors:  Manas Ranjan Dikhit; Akhilesh Kumar; Sushmita Das; Budheswar Dehury; Ajaya Kumar Rout; Fauzia Jamal; Ganesh Chandra Sahoo; Roshan Kamal Topno; Krishna Pandey; V N R Das; Sanjiva Bimal; Pradeep Das
Journal:  Front Immunol       Date:  2017-12-14       Impact factor: 7.561

Review 4.  Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.

Authors:  Nicky Didwania; Md Shadab; Abdus Sabur; Nahid Ali
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

5.  In silico analysis and expression of a new chimeric antigen as a vaccine candidate against cutaneous leishmaniasis.

Authors:  Leila Motamedpour; Abdolhossein Dalimi; Majid Pirestani; Fatemeh Ghaffarifar
Journal:  Iran J Basic Med Sci       Date:  2020-11       Impact factor: 2.699

6.  Pharmacokinetic and molecular docking studies to design antimalarial compounds targeting Actin I.

Authors:  Vandana Guleria; Tarun Pal; Bhanu Sharma; Shweta Chauhan; Varun Jaiswal
Journal:  Int J Health Sci (Qassim)       Date:  2021 Nov-Dec

7.  Immunoinformatics and molecular dynamics approaches: Next generation vaccine design against West Nile virus.

Authors:  Md Tahsin Khan; Rahatul Islam; Tarhima Jahan Jerin; Araf Mahmud; Sahara Khatun; Ahasanul Kobir; Md Nahidul Islam; Arzuba Akter; Shakhinur Islam Mondal
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

8.  Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii.

Authors:  Vandana Solanki; Vishvanath Tiwari
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

9.  Overlapping CD8+ and CD4+ T-cell epitopes identification for the progression of epitope-based peptide vaccine from nucleocapsid and glycoprotein of emerging Rift Valley fever virus using immunoinformatics approach.

Authors:  Utpal Kumar Adhikari; M Mizanur Rahman
Journal:  Infect Genet Evol       Date:  2017-11-01       Impact factor: 3.342

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.